(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 May 2021 (20.05.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/095840 A1

(51) International Patent Classification:
A61K 31/40 (2006.01) *A61P 35/02* (2006.01)

(21) International Application Number:
PCT/JP2020/042410

(22) International Filing Date:
13 November 2020 (13.11.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/934,923 13 November 2019 (13.11.2019) US

(71) Applicants: **TAIHO PHARMACEUTICAL CO., LTD.** [JP/JP]; 1-27, Kandanishiki-cho, Chiyoda-ku, Tokyo, 1018444 (JP). **ASTEX PHARMACEUTICALS, INC.** [US/US]; 4420 Rosewood Drive, Suite 200, Pleasanton, California, 94588 (US).

(72) Inventors: **HITOTSUMACHI, Hiroko**; c/o TAIHO PHARMACEUTICAL CO., LTD., 3, Okubo, Tsukuba-shi, Ibaraki, 3002611 (JP). **MACHIDA, Takumitsu**; c/o TAIHO PHARMACEUTICAL CO., LTD., 3, Okubo, Tsukuba-shi, Ibaraki, 3002611 (JP). **YAMADA, Masaki**; c/o TAIHO PHARMACEUTICAL CO., LTD., 3, Okubo, Tsukuba-shi, Ibaraki, 3002611 (JP). **KEER, Harold**; c/o Astex Pharmaceuticals, Inc., 4420 Rosewood Drive, Suite 200, Pleasanton, California, 94588 (US). **OGANESIAN, Aram**; c/o Astex Pharmaceuticals, Inc., 4420 Rosewood Drive, Suite 200, Pleasanton, California, 94588 (US).

(74) Agent: **SAEGUSA & PARTNERS**; Kitahama Konishi Building, 1-7-1, Doshomachi, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2021/095840 A1

(54) Title: METHODS OF TREATING LSD1-RELATED DISEASES and Disorders WITH LSD1 INHIBITORS

(57) Abstract: A method of treating an LSD1-related disease or disorder in a patient in need, the method comprising administering an effective amount of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof to the patient on an administration schedule comprising daily dosing for one week or two weeks, followed by a resting period of one week.